Amplia Therapeutics Limtied (ASX:ATX) have undertaken a capital raising.
What are the key highlights?
- $0.93 million raised.
- Platinum International Healthcare Fund participated in the placement which was managed by Taylor Collison.
- The new capital will enable the Company to complete the clinic-enabling studies. The Company remains on track to initiate clinical trials of its lead FAK inhibitor, AMP945, during 2020.